GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
About the study
This is a phase II, multicenter, open-label study to evaluate the antitumor activity, efficacy and safety of GEN-001 in combination with avelumab as a third line (3L) or greater line treatment which is not received the Standard of Care (SOC) for patients with PD-L1 positive advanced GC/Gastroesophageal Junction Adenocarcinoma who are not received cancer immunotherapy regimens as mono or combination therapy.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histologically confirmed unresectable, recurrent, locally advanced or metastatic GC/Gastroesophageal Junction Adenocarcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Have adequate organ functions as defined in the protocol
- Negative childbearing potential
- Have experienced documented objective radiographic or clinical disease progression after 2 or above previous lines of standard therapy.
- PD-L1 positive
- Measurable disease as per RECIST v1.1 defined as at least 1 lesion
- Estimated life expectancy of at least 3 months
- Have ability to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities
EXCLUSION CRITERIA
Exclusion Criteria:
- Previously received T-cell coregulatory protein inhibitors
- Has clinically significant evidence of ascites by physical exam
- Known prior severe hypersensitivity reactions to monoclonal antibodies or any component in their formulation
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Current use of immunosuppressive medication
- Have an active infection requiring antibiotics, antifungal or antiviral agents or have received a course of antibiotics within 4 weeks
- Has received a live vaccine within 4 weeks
- Known history or any evidence of active for non-infectious pneumonitis
- Prior solid organ or allogeneic stem cell transplantation
- Has had any investigational or anti-tumor treatment within 4 weeks or 5 half-life periods of starting study treatment, had any major surgeries within 4 weeks
- Has received proton pump inhibitors (PPIs) within 2 weeks
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has clinically significant (i.e., active) cardiovascular disease
- Has other persisting toxicities
- Has other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, or psychiatric conditions
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Gastric Cancer,Gastroesophageal Junction Adenocarcinoma
Age (in years)
19+
Phase
Phase 2
Participants needed
42
Est. Completion Date
Dec 31, 2024
Treatment type
Interventional
Sponsor
Genome & Company
ClinicalTrials.gov identifier
NCT05419362
Study number
[GNC] GEN001-201
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?